Objective  To explore the effects of Tanganjianwan (TGJW) combined with abdominal massage (AM) on glucose and lipid metabolism and inflammatory factors in obesity and type 2 diabetes mellitus (OT2DM) patients with metformin treatment.

Methods  Patients with OT2DM diagnosed in Wuhan Hospital of Traditional Chinese Medicine from June 2021 to June 2023 were included as study subjects, and were divided into the AM group (metformin combined with AM) and the TGJW group (metformin combined with AM+TGJW) according to the random number table method. The treatment efficacy and safety were assessed by continuous intervention for 3 months. Obesity-related indices [waist-hip ratio (WHR) and body mass index (BMI)], glycemic and lipid metabolic indices [glycosylated hemoglobin (HbA1c), fasting blood glucose (FBG), postprandial 2-hour glucose (P2hG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)], insulin sensitivity indexes [homeostasis model insulin resistance index (HOMA-IR) and homeostasis model pancreatic β-cell function index (HOMA-β)], and inflammation indexes [interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), and C-reactive protein (CRP)] changes were compared before and after treatment between the TGJW group and the AM group.

Results  A total of 100 OT2DM patients were included in the study, with 50 cases each in the TGJW group and AM group. After the intervention, the treatment efficiency of the TGJW group was significantly higher than that of the AM group (P<0.05), and no malignant adverse events occurred during treatment. Compared with the pre-treatment period, the levels of WHR, BMI, FBG, P2hG, HbA1c, TC, TG, LDL-C, HOMA-IR, IL-6, TNF-α, and CRP decreased in both groups (P<0.05), while the levels of HDL-C and HOMA-β increased significantly (P<0.05). After the intervention, the levels of WHR, BMI, FBG, P2hG, HbA1c, TC, TG, LDL-C, HOMA-IR, IL-6, TNF-α, and CRP in the TGJW group were lower than those in the AM group (P<0.05), while the levels of HDL-C and HOMA-β were higher than those in the AM group (P<0.05).

Conclusion  Compared with AM treatment alone, TGJW combined with AM can improve glucose-lipid metabolism, insulin sensitivity and inflammation indexes in OT2DM patients, enhance the therapeutic effect of metformin treatment in OT2DM patients, and is safe, it has certain clinical promotion significance.

1.叶雯, 刘怀珍. 中药联合利拉鲁肽治疗2型糖尿病合并肥胖的Meta分析[J]. 云南中医中药杂志, 2024, 45(2): 40-46. [Ye W, Liu HZ. Meta-analysis of Chinese medicine combined with liraglutide in the treatment of type 2 diabetes with obesity[J]. Yunnan Journal of Traditional Chinese Medicine, 2024, 45(2): 40-46.] DOI: 10.16254/j. cnki.53-1120/r.2024.02.002.

2.蔡宏桂, 姚南珍, 李思韵, 等. 茵陈五苓散联合利拉鲁肽对肥胖型2型糖尿病患者糖脂代谢、胰岛素敏感性和氧化应激的影响[J]. 现代生物医学进展, 2024, 24(1): 162-166. [Cai HG, Yao NZ, Li SY, et al. Effects of Yinchen Wuling powder and lilalutide on glucose and lipid metabolism, insulin sensitivity and oxidative stress in obese type 2 diabetes patients[J]. Modern Biomedical Progress, 2024, 24(1): 162-166.] DOI: 10.13241/j.cnki.pmb.2024.01.032.

3.李孟英, 王德满. 肥胖型2型糖尿病内科治疗研究进展[J]. 社区医学杂志, 2020, 18(7): 549-552. [Li MY, Wang DM. Research progress in medical treatment of obese type 2 diabetes[J]. Journal of Community Medicine, 2020, 18(7): 549-552.] DOI: 10.19790/j.cnki.JCM.2020.07.21.

4.朱洁云, 朱良峰, 潘冬赞, 等. 奥利司他治疗超重和肥胖2型糖尿病疗效和安全性的Meta分析[J]. 中国循证医学杂志, 2022, 22(9): 1020-1026. [Zhu JY, Zhu LF, Pan DZ, et al. Meta-analysis of efficacy and safety of orlistat in the treatment of overweight and obese type 2 diabetes[J]. Chinese Journal of Evidence Based Medicine, 2022, 22(9): 1020-1026.] DOI: 10.7507/1672-2531.202201086.

5.李敏, 高瑞超, 张志佳, 等. 利拉鲁肽对腹型肥胖2型糖尿病患者肠道菌群及脂肪细胞因子水平的影响 [J]. 药物流行病学杂志, 2022, 31(12): 794-798. [Li M, Gao RC, Zhang ZJ, et al. Effect of lilalutide on intestinal flora and adipocytokines in abdominal obesity type 2 diabetes[J]. Chinese Journal of Pharmacoepidemiology, 2022, 31(12): 794-798.] DOI: 10.19960/j.cnki.issn1005-0698.2022.12.002.

6.林琴, 彭德忠, 包锐, 等. 推拿疗法治疗2型糖尿病研究进展[J]. 中国疗养医学, 2017, 26(10): 1033-1035. [Lin Q, Peng DZ, Bao R, et al. Research progress on massage therapy for type 2 diabetes[J]. Chinese Journal of Rehabilitation Medicine, 2017, 26(10): 1033-1035.] DOI: 10.13517/j.cnki.ccm.2017.10.009.

7.吴莹, 张义生, 范彦博. 糖肝煎浓缩丸水提部分的提取工艺研究[J]. 中国药师, 2016, 19(7): 1236-1238. [Wu Y, Zhang YS, Fan YB. Research on the extraction process of water extracted part of tanggan jian concentrated pills[J]. China Pharmacist, 2016, 19(7): 1236-1238.] DOI: 10.3969/j.issn.1008-049X.2016.07.003.

8.曾晓语. 糖肝煎丸治疗肝郁脾虚、湿热内蕴型2型糖尿病的临床研究[D]. 武汉: 湖北中医药大学, 2019.

9.中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J]. 中华内分泌代谢杂志, 2014, 30(8): 893-942. DOI: 10.3760/cma.j.issn.1000-6699.2014.10.020.

10.李春生. 现代肥胖病学[M]. 北京: 科学技术文献出版社, 2004: 518-524.

11.钱瑜. 利拉鲁肽注射液联合恩格列净片治疗肥胖2型糖尿病的临床效果[J]. 临床合理用药, 2023, 16(26): 81-84. [Qian Y. Clinical effect of liraglutide injection combined with engelijing tablets in the treatment of obese type 2 diabetes[J]. Chinese Journal of Clinical Rational Drug Use , 2023, 16(26): 81-84.] DOI: 10.15887/j.cnki. 13-1389/r.2023.26.021.

12.Ruze R, Liu TT, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments[J]. Front Endocrinol (Lausanne), 2023, 14: 1161521. DOI: 10.3389/fendo.2023.1161521.

13.刘芳钰, 冷锦红. 从脾论治脂肪组织参与肥胖型胰岛素抵抗[J]. 中国中医药图书情报杂志, 2024, 48(2): 20-24. [Liu FY, Leng JH. Treating obesity-related insulin resistance from the spleen perspective[J]. Journal of Chinese Medicine and Library Information, 2024, 48(2): 20-24.] DOI: 10.3969/j.issn.2095-5707.202303072.

14.刘超, 王琳, 姚凤云, 等. 加味温胆汤调控NF-κB/NLRP3通路干预炎性反应抗大鼠糖尿病动脉粥样硬化的机制[J]. 中国实验方剂学杂志, 2024-01-17: 1-9. [Liu C, Wang L, Yao FY, et al. Modified wendan tang regulates NF-κ the mechanism of B/NLRP3 pathway intervening inflammatory response against atherosclerosis in rats with diabetes[J]. Chinese Journal of Experimental Formula Studies, 2024-01-17: 1-9.] DOI: 10.13422/j.cnki.syfjx.20240521.

15.金徐燕, 童海航, 谢妙时. 消渴方加减联合达格列净治疗2型糖尿病临床研究[J]. 新中医, 2024, 56(2): 79-83. [Jin XY, Tong HH, Xie MS. Clinical study on the treatment of type 2 diabetes with xiaoke recipe plus daggligin[J]. New Traditional Chinese Medicine, 2024, 56(2): 79-83.] DOI: 10.13457/j.cnki.jncm.2024.02.015.

16.李纪新, 邱林杰, 任燕, 等. 中药及活性成分靶向M1/ M2巨噬细胞极化平衡干预肥胖合并2型糖尿病的研究进展[J]. 中国中药杂志, 2024-02-20: 1-12. [Li JX, Qiu LJ, Ren Y, et al. Research progress of Chinese medicine and active ingredients targeting M1/M2 macrophage polarization balance intervention in obesity with type 2 diabetes[J]. Chinese Journal of Traditional Chinese Medicine, 2024-02-20: 1-12.] DOI: 10.19540/j.cnki.cjcmm.20240205.703.

17.吴晓婧, 罗琼. 妊娠期糖尿病子代近远期健康影响及机制研究进展[J]. 实用妇产科杂志, 2024, 40(1): 9-14. [Wu XJ, Luo Q. Recent and long-term health effects and mechanisms of diabetes during pregnancy offspring[J]. Journal of Practical Obstetrics and Gynecology, 2024, 40(1): 9-14.] https://www.nstl.gov.cn/paper_detail.html?id=3ae32a2ba5185e78d4a066a35b29dfb6.

18.李秀, 李兴茂, 王婷,等. 胰高血糖素样肽1受体激动剂治疗代谢相关脂肪性肝病作用机制研究进展[J]. 山东医药, 2023, 63(32): 88-91. [Li X, Li XM, Wang T, et al. Progress in the mechanism of glucagon-like peptide-1 receptor agonists in the treatment of metabolic-related fatty liver disease[J]. Shandong Medical Journal, 2023, 63(32): 88-91.] DOI: 10.3969/j.issn.1002-266X.2023.32.021.